Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.

Scientific reports - 17 Feb 2022

Vaclova Tereza, Chakraborty Atanu, Sherwood James, Ross Sarah, Carroll Danielle, Barrett J Carl, Downward Julian, de Bruin Elza C

Abstract excerpt

The development of covalent inhibitors against KRAS G12C represents a major milestone in treatment of RAS-driven cancers, especially in non-small cell lung cancer (NSCLC), where KRAS G12C is one of the most common oncogenic driver. Here we investigated if additional KRAS mutations co-occur with KRAS G12C (c.34G>T) in NSCLC tumours and if such mutation co-occurrence affects cellular response to G12C-specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Enzyme Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Mutation Rate

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35177674
DOI: 10.1038/s41598-022-06369-3
PMCID: PMC8854729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.PMID 35177674Read ↗

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read ↗

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.Semantic proximity Read ↗

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancerSemantic proximity Read ↗

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.Semantic proximity Read ↗

Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer.Semantic proximity Read ↗

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.Semantic proximity Read ↗

Current perspectives of KRAS in non-small cell lung cancer.Semantic proximity Read ↗

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.Semantic proximity Read ↗

The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer PatientsSemantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.Semantic proximity Read ↗

Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.